Table 1 Demographic, clinicopathological characteristics and treatment information of all, training and validation cohort
From: Development and validation of a nomogram to predict cancer-specific survival of uveal melanoma
All patients (n = 839) | Training cohort (n = 588) | Validation cohort (n = 251) | P-value | ||
|---|---|---|---|---|---|
Age, y, median (IQR) | 60 (51,69) | 60 (52,69) | 60 (51,68) | 0.492 | |
Age, n (%) | 0.484 | ||||
≤58 | 379 (45.2) | 261 (44.4) | 118 (47.0) | ||
> 58 | 460 (54.8) | 327 (55.6) | 133 (53.0) | ||
Gender, n (%) | 0.637 | ||||
Female | 374 (44.6) | 259 (44.0) | 115 (45.8) | ||
Male | 465 (55.4) | 329 (56.0) | 136 (54.2) | ||
Race, n (%) | 0.352 | ||||
White | 812 (96.8) | 568 (96.6) | 244 (97.2) | ||
Black | 13 (1.6) | 8 (1.4) | 5 (2.0) | ||
Other | 14 (1.7) | 12 (2.0) | 2 (0.8) | ||
Marriage, n (%) | 0.188 | ||||
Married | 467 (55.7) | 326 (55.4) | 141 (56.2) | ||
Unmarried | 296 (35.3) | 202 (34.4) | 94 (37.5) | ||
Unknown | 76 (9.1) | 60 (10.2) | 16 (6.4) | ||
Insurance, n (%) | 0.173 | ||||
Medicaid | 77 (9.2) | 60 (10.2) | 17 (6.8) | ||
Insured | 721 (85.9) | 497 (84.5) | 224 (89.2) | ||
Uninsured | 30 (3.6) | 21 (3.6) | 9 (3.6) | ||
Unknown | 11 (1.3) | 10 (1.7) | 1 (0.4) | ||
Primary site, n (%) | 0.679 | ||||
Chorioid | 738 (88.0) | 519 (88.3) | 219 (87.3) | ||
Cilliary body and iris | 101 (12.0) | 69 (11.7) | 32 (12.8) | ||
Laterality, n (%) | 0.886 | ||||
Left | 418 (49.8) | 292 (49.7) | 126 (50.2) | ||
Right | 421 (50.2) | 296 (50.3) | 125 (49.8) | ||
Histological type, n (%) | 0.563 | ||||
Spindle cell melanoma | 144 (17.2) | 107 (18.2) | 37 (14.7) | ||
Mixed epithelioid and spindle cell melanoma | 116 (13.8) | 78 (13.3) | 38 (15.1) | ||
Epithelioid cell melanoma | 44 (5.2) | 29 (4.9) | 15 (6.0) | ||
Other | 535 (63.8) | 374 (63.6) | 161 (64.1) | ||
Stage, n (%) | 0.480 | ||||
I | 159 (19.0) | 117 (20.0) | 42 (16.7) | ||
IIa | 260 (31.0) | 180 (30.6) | 80 (31.9) | ||
IIb | 172 (20.5) | 125 (21.3) | 47 (18.7) | ||
IIIa | 134 (16.0) | 89 (15.1) | 45 (17.9) | ||
IIIb | 74 (8.8) | 52 (8.8) | 22 (8.8) | ||
IIIc | 16 (1.9) | 12 (2.0) | 4 (1.6) | ||
IV | 24 (2.9) | 13 (2.2) | 11 (4.4) | ||
T stage, n (%) | 0.976 | ||||
T1 | 203 (24.2) | 144 (24.5) | 59 (23.5) | ||
T2 | 254 (30.3) | 179 (30.4) | 75 (29.9) | ||
T3 | 236 (28.1) | 163 (27.7) | 73 (29.1) | ||
T4 | 146 (17.4) | 102 (17.4) | 44 (17.5) | ||
N stage, n (%) | 0.621 | ||||
N0 | 834 (99.4) | 585 (99.5) | 249 (99.2) | ||
N1 | 5 (0.6) | 3 (0.5) | 2 (0.8) | ||
M stage, n (%) | 0.150 | ||||
M0 | 816 (97.3) | 575 (97.8) | 241 (96.0) | ||
M1 | 23 (2.7) | 13 (2.2) | 10 (4.0) | ||
Metastasis at bone, n (%) | 0.179 | ||||
Yes | 5 (0.6) | 2 (0.3) | 3 (1.2) | ||
No | 831 (99.1) | 583 (99.2) | 248 (98.8) | ||
Unknown | 3 (0.4) | 3 (0.5) | 0 (0) | ||
Metastasis at liver, n (%) | 0.293 | ||||
Yes | 17 (2.0) | 9 (1.5) | 8 (3.2) | ||
No | 819 ((97.6) | 577 (98.1) | 2 (96.4) | ||
Unknown | 3 (0.4) | 2 (0.3) | 1 (0.4) | ||
Metastasis at brain, n (%) | |||||
Yes | 0 (0) | 0 (0) | 0 (0) | 0.355 | |
No | 837 (99.8) | 586 (99.7) | 251 (100) | ||
Unknown | 2 (0.2) | 2 (0.3) | 0 (0) | ||
Metastasis at lung, n (%) | 0.647 | ||||
Yes | 3 (0.4) | 2 (0.3) | 1 (0.4) | ||
No | 834 (99.4) | 584 (99.3) | 250 (99.6) | ||
Unknown | 2 (0.2) | 2 (0.3) | 0 (0) | ||
Historic stage, n (%) | 0.192 | ||||
Localized | 752 (89.6) | 526 (89.5) | 226 (90.0) | ||
Regional | 64 (7.6) | 49 (8.3) | 15 (6.0) | ||
Distant | 23 (2.7) | 13 (2.2) | 10 (4.0) | ||
SSF2-Measured basal diameter, mm, median | 12 (8.5, 15.3) | 12 (8.4,15) | 12 (9,16) | 0.316 | |
SSF3-Measured thickness (Depth),mm, median | 5.4 (3.1,9.5) | 5.4 (3.2,9.2) | 5.3 (3,9.8) | 0.888 | |
Surgery, n (%) | 0.508 | ||||
No | 450 (53.6) | 311 (52.9) | 139 (55.4) | ||
Yes | 389 (46.4) | 277 (47.1) | 112 (44.6) | ||
Radiotherapy, n (%) | 0.451 | ||||
No | 344 (41) | 246 (41.8) | 98 (39.0) | ||
Yes | 495 (59) | 342 (58.2) | 153 (61.0) | ||
Chemotherapy, n (%) | 0.500 | ||||
No | 814 (97.0) | 572 (97.3) | 242 (96.4) | ||
Yes | 25 (3.0) | 16 (2.7) | 9 (3.6) | ||